Intravenous immunoglobulin for myasthenia gravis.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.cd002277PMID 12804431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved

  2025cites this paper
• Effect of Intravenous Immunoglobulin or Plasmapheresis in Myasthenic Crisis and Worsening Myasthenia Gravis Compared With or Without Rescue Treatment.

  2025cites this paper
• Intravenous use of immunoglobulins for the treatment of diseases of the central and peripheral nervous system

  2025cites this paper
• Recommendations for the management of myasthenia gravis in Belgium

  2024cites this paper
• Targeted Treatments for Myasthenia Gravis in Children and Adolescents

  2024cites this paper
• Comparative Analysis of Intravenous Immunoglobulins (IVIg) vs Plasmapheresis (PLEX) in the Management of Myasthenic Crisis

  2024cites this paper
• Myasthenia gravis with toxic goiter: Challenges with management in a low-resource setting in Africa; Review of literature and case report

  2024cites this paper
• Drug Use Patterns in Myasthenia Gravis: A Real-World Population-Based Cohort Study in Italy

  2024cites this paper
• Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double‐blind, placebo‐controlled trial

  2024cites this paper
• Utilization of phase I studies for target validation of first-in-class drugs.

  2024cites this paper
• Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future

  2024cites this paper
• Impaired cerebral microvascular endothelial cells integrity due to elevated dopamine in myasthenic model

  2024cites this paper
• Myasthenia gravis – Schritt für Schritt

  2024cites this paper
• Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series.

  2024cites this paper
• Phase 2 trial in acetylcholine receptor antibody‐positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study

  2023cites this paper
• Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review

  2023cites this paper
• Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee

  2023influential citation
• Guideline for the management of myasthenic syndromes

  2023cites this paper
• Myasthenia gravis, respiratory function, and respiratory tract disease

  2023cites this paper
• Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events

  2023cites this paper
• Therapeutic Plasma Exchange among Myasthenia Gravis Patients Attended at Referral Neurosciences Hospital in Bangladesh: A Single Centre Experience

  2023cites this paper
• Thawed plasma (TP) as a substitute for intravenous immune globulin (IVIG) to prevent hypogammaglobulinemia post-therapeutic plasma exchange.

  2023cites this paper
• Weaning and extubation failure in myasthenic crisis: a multicenter analysis

  2023cites this paper
• Pharmacological treatment of Lambert-Eaton Myasthenic Syndrome

  2023influential citation
• Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis

  2022cites this paper
• Effects of intravascular photobiomodulation on motor deficits and brain perfusion images in intractable myasthenia gravis: A case report

  2022cites this paper
• Myasthenia gravis—treatment and severity in nationwide cohort

  2022cites this paper
• Outcomes and characteristics of myasthenia gravis: A 10-year retrospective cross-sectional study at King Fahad Medical City

  2022cites this paper
• Current Treatment of Myasthenia Gravis

  2022cites this paper
• Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis

  2022cites this paper
• Iranian Consensus Recommendations for Treatment of Myasthenia Gravis.

  2022cites this paper
• Therapeutic plasma exchange for myasthenia gravis, Guillain-Barre syndrome, and other immune-mediated neurological diseases, over a 40-year experience

  2022cites this paper
• Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals

  2022cites this paper
• Inhibition of TNF-α Restores Muscle Force, Inhibits Inflammation, and Reduces Apoptosis of Traumatized Skeletal Muscles

  2022cites this paper
• Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management

  2022cites this paper
• Neonatal Fc Receptor–Targeted Therapies in Neurology

  2022cites this paper
• Heterogeneity in myasthenia gravis: considerations for disease management

  2021cites this paper
• Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States

  2021cites this paper
• Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence

  2021cites this paper
• Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis

  2021cites this paper
• Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy

  2021cites this paper
• Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis

  2021cites this paper
• Role of Therapeutic Plasma Exchange in the Treatment of Myasthenia Gravis: A Tertiary Hospital - Based Observational Study

  2021influential citation
• Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten

  2021cites this paper
• Immunoglobulin Replacement Therapy

  2021cites this paper
• Current and Upcoming Treatment Modalities in Myasthenia Gravis

  2021cites this paper
• History of Myasthenia Gravis Revisited.

  2021cites this paper
• Neuromuscular Respiratory Failure.

  2021cites this paper
• TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE

  2021cites this paper
• Treatment of refractory myasthenia gravis by double‐filtration plasmapheresis and rituximab: A case series of nine patients and literature review

  2020cites this paper
• What Makes Antibodies Against G Protein-Coupled Receptors so Special? A Novel Concept to Understand Chronic Diseases

  2020cites this paper
• Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis

  2020cites this paper
• Chronic immunoglobulin maintenance therapy in myasthenia gravis

  2020cites this paper
• Immunoglobulin Therapy

  2020cites this paper
• Management of Myasthenia Gravis During COVID-19 Pandemic

  2020cites this paper
• Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders

  2020cites this paper
• Should we prevent thrombosis related to intravenous immunoglobulin infusions with systematic anticoagulant prophylaxis?

  2020cites this paper
• Update on immune‐mediated therapies for myasthenia gravis

  2020cites this paper
• Study of use of intravenous immunoglobulin in pediatric intensive care unit in a tertiary care center: An audit and review of evidence

  2020influential citation
• Miastenia e sindromi miasteniche

  2020cites this paper
• Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.

  2020cites this paper
• Therapeutic Apheresis

  2020cites this paper
• Understanding the burden of refractory myasthenia gravis

  2019cites this paper
• A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations

  2019cites this paper
• Generation of two high affinity anti‐mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia

  2019cites this paper
• Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series

  2019cites this paper
• Human Immunoglobulin Preparations

  2019cites this paper
• The placebo response in myasthenia gravis assessed by quantitative myasthenia gravis score: A meta‐analysis

  2019cites this paper
• Myasthenia gravis

  2019cites this paper
• Myasthenia Gravis and Congenital Myasthenic Syndromes.

  2019cites this paper
• Myasthenic crisis demanding mechanical ventilation

  2019cites this paper
• Maintenance immunosuppression in myasthenia gravis, an update.

  2019cites this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

  2019cites this paper
• Immunoglobulins in neurological practice: a review of the literature

  2019cites this paper
• Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies

  2018cites this paper
• Consenso Mexicano para la prescripción de inmunoglobulina G como tratamiento de reemplazo e inmunomodulación

  2018cites this paper
• Myasthenic crisis

  2018cites this paper
• Critical Care of Neuromuscular Disorders

  2018cites this paper
• Myasthénies et syndromes myasthéniques

  2018cites this paper
• Myasthenic ophthalmoparesis: Time To resolution after initiating immune therapies

  2018cites this paper
• Myasthenia Gravis and Related Disorders

  2018cites this paper
• Neuromuscular Disorders

  2018cites this paper
• Update on ocular myasthenia gravis in Taiwan

  2018cites this paper
• Myasthenia Gravis – A Review of Current Therapeutic Options

  2018cites this paper
• CTLA-4 methylation regulates the pathogenesis of myasthenia gravis and the expression of related cytokines

  2018cites this paper
• Risk factors of myasthenic crisis after thymectomy for thymoma patients with myasthenia gravis†

  2017cites this paper
• Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature

  2017cites this paper
• Update on the use of immunoglobulin in human disease: A review of evidence

  2017influential citation
• Evidence-Based Critical Care: A Case Study Approach

  2017influential citation
• [Colombian Guidelines of clinical practice for the use of immunoglobulins in the treatment of replacement and immunomodulation].

  2017cites this paper
• Subcutaneous immunoglobulin in myasthenia gravis exacerbation

  2017cites this paper
• Audit of provincial IVIG Request Forms and efficacy documentation in four Ontario tertiary care centres

  2017cites this paper
• Myasthenia gravis: recent advances in immunopathology and therapy

  2017cites this paper
• The Production Processes and Biological Effects of Intravenous Immunoglobulin

  2016cites this paper
• Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab

  2016cites this paper
• The Effect of Immunonutrition on the Postoperative Complications in Thymoma with Myasthenia Gravis

  2016cites this paper
• Getting Rid of Weakness in the ICU: An Updated Approach to the Acute Management of Myasthenia Gravis and Guillain-Barré Syndrome

  2016cites this paper
• Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

  2016cites this paper
• Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study

  2016cites this paper
• Predictors of extubation outcomes following myasthenic crisis

  2016cites this paper